Ophthotech Corp. (OPHT)

2.62
0.03 1.10
NASDAQ : Health Technology
Prev Close 2.65
Open 2.65
Day Low/High 2.62 / 2.72
52 Wk Low/High 2.24 / 3.60
Volume 53.16K
Avg Volume 264.20K
Exchange NASDAQ
Shares Outstanding 36.15M
Market Cap 96.88M
EPS 3.20
P/E Ratio 0.85
Div & Yield N.A. (N.A)

Latest News

Ophthotech Reports Fourth Quarter And Full Year 2017 Financial And Operating Results

Ophthotech Reports Fourth Quarter And Full Year 2017 Financial And Operating Results

Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the fourth quarter and full year ended December 31, 2017 and provided a business update.

Ophthotech Targets Gene Therapy To Expand Its Orphan And Age-Related Retinal Disease Strategy

Ophthotech Targets Gene Therapy To Expand Its Orphan And Age-Related Retinal Disease Strategy

Ophthotech Corporation (NASDAQ:OPHT) announced today that the Company has initiated an innovative gene therapy research collaboration focused on applying novel gene therapy technology to discover and develop next-generation...

Ophthotech Corporation To Report Fourth Quarter And Full Year 2017 Financial Results And Host Conference Call On Tuesday, February 27, 2018

Ophthotech Corporation To Report Fourth Quarter And Full Year 2017 Financial Results And Host Conference Call On Tuesday, February 27, 2018

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its fourth quarter and full year 2017 financial and operating results on Tuesday, February 27, 2018.

Ophthotech Announces First Patient Enrolled In The Phase 2b Clinical Trial Of Zimura®, Complement C5 Inhibitor, For The Treatment Of Autosomal Recessive Stargardt Disease (STGD1)

Ophthotech Announces First Patient Enrolled In The Phase 2b Clinical Trial Of Zimura®, Complement C5 Inhibitor, For The Treatment Of Autosomal Recessive Stargardt Disease (STGD1)

Ophthotech Corporation (NASDAQ:OPHT) announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura ®...

Ophthotech Announces Election Of Jane Pritchett Henderson, Chief Financial Officer And Senior Vice President Of Corporate Development At Voyager Therapeutics, To Its Board Of Directors

Ophthotech Announces Election Of Jane Pritchett Henderson, Chief Financial Officer And Senior Vice President Of Corporate Development At Voyager Therapeutics, To Its Board Of Directors

Ophthotech Corporation (NASDAQ: OPHT) announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors,...

Ophthotech Corporation To Present At The 36th Annual J.P. Morgan Healthcare Conference

Ophthotech Corporation To Present At The 36th Annual J.P. Morgan Healthcare Conference

Ophthotech Corporation (NASDAQ: OPHT) announced today that Glenn P.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APEI, CMP, FRPT, GLP, OPHT, SEE, TA, TIS, VRTS Downgrades: BCRH, CAFD, KO, REGN, TERP Initiations: CRSP Read on to get TheStreet Quant Ratings' detailed report:

Ophthotech Soars After Third-Quarter Results -- Biotech Movers

Ophthotech Soars After Third-Quarter Results -- Biotech Movers

The New York-based firm reported net income of $5.25 per share, compared with a net loss of $1.71 per share, in the same period a year ago.

Ophthotech Reports Third Quarter 2017 Financial And Operating Results

Ophthotech Reports Third Quarter 2017 Financial And Operating Results

Ophthotech Corporation (Nasdaq: OPHT) today announced financial and operating results for the third quarter ended September 30, 2017 and provided a business update.

Ophthotech Corporation To Report Third Quarter 2017 Financial Results And Host Conference Call On Wednesday, November 8, 2017

Ophthotech Corporation To Report Third Quarter 2017 Financial Results And Host Conference Call On Wednesday, November 8, 2017

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter 2017 financial and operating results on Wednesday, November 8, 2017.

Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

The Fremont, Calif.-based firm has unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.

Ophthotech Provides Update On Zimura® Complement Programs For Treatment Of Eye Diseases

Ophthotech Provides Update On Zimura® Complement Programs For Treatment Of Eye Diseases

Ophthotech Corporation (NASDAQ: OPHT) announced today the initiation of an open-label Phase 2a clinical trial of Zimura ® (avacincaptad pegol), the Company's complement factor C5 inhibitor, in patients with wet...

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

Ophthotech Announces Results From Third Phase 3 Trial Of Fovista® In Wet Age-Related Macular Degeneration

Ophthotech Announces Results From Third Phase 3 Trial Of Fovista® In Wet Age-Related Macular Degeneration

Ophthotech Corporation (Nasdaq:OPHT) today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its Phase 3 clinical trial investigating the...

Ophthotech Reports Second Quarter 2017 Financial And Operating Results

Ophthotech Reports Second Quarter 2017 Financial And Operating Results

Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the second quarter ended June 30, 2017 and provided a business update on its strategic plan.

Ophthotech Expands Focus With Development For Ophthalmic Orphan Diseases

Ophthotech Expands Focus With Development For Ophthalmic Orphan Diseases

Ophthotech Corporation (Nasdaq:OPHT) today announced that the Company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic...

Ophthotech Corporation To Report Second Quarter 2017 Financial Results And Host Conference Call On Wednesday, July 26, 2017

Ophthotech Corporation To Report Second Quarter 2017 Financial Results And Host Conference Call On Wednesday, July 26, 2017

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its second quarter 2017 financial and operating results on Wednesday, July 26, 2017.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Ophthotech Corp. - OPHT

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ophthotech Corp.

Ophthotech Reports First Quarter 2017 Financial And Operating Results

Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the first quarter ended March 31, 2017 and provided a general business update.

Ophthotech Corporation To Report First Quarter 2017 Financial Results And Host Conference Call On Wednesday, May 3, 2017

Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its first quarter 2017 financial and operating results on Wednesday, May 3, 2017.

Ophthotech Announces Leadership Transition Effective July 1, 2017

Ophthotech Corporation (Nasdaq:OPHT) today announced that David R.

SHAREHOLDER COMPLAINT: Levi & Korsinsky, LLP Reminds Investors Of Ophthotech Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation ("Ophthotech") (NASDAQ:OPHT) between May 11,...

Ophthotech Corporation Selected Financial Data (unaudited) (in Thousands, Except Per Share Data)

Ophthotech Corporation (Nasdaq:OPHT) today announced financial and operating results for the fourth quarter and full year ended December 31, 2016 and provided a general business update.

OPHT SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ophthotech Corporation And A Lead Plaintiff Deadline Of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Ophthotech Corporation (NASDAQ: OPHT) securities...

Ophthotech Corporation To Report Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call On Tuesday, February 28, 2017

Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its fourth quarter and full year 2016 financial and operating results on Tuesday, February 28, 2017.

INVESTOR COMPLAINT: Levi & Korsinsky, LLP Reminds Investors Of Ophthotech Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 13, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation ("Ophthotech") (NASDAQ: OPHT) between May...

TheStreet Quant Rating: D+ (Sell)